Persantine: Variation in Response Trial

Stopped early · Phase 4

Conditions studied: Coronary Artery Disease

In brief

The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.

Key facts

Study ID

NCT00763009

Run by

UConn Health

People needed

8

Starts

2002-09-01

Expected to finish

2009-07-01

Last updated by the study team

2018-04-13

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients > 21 years old
• Patient undergoing cardiac catheterization with planned PTCA or with a significant coronary lesion of either the LAD or Circumflex

You may not qualify if…

• Theophylline or oral Persantine use in 24hrs
• Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker
• Active asthma or bronchospasm
• Patients with severe hepatic insufficiency
• Patients experiencing an acute transmural infarction at the time of the index visit
• Conditions that are known to affect resistive vessel function or myocardial flow

Where it is running

• UCONN Health Center — Farmington, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.